A Phase II, Open-label, Multi-center Study of Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma.

Trial Profile

A Phase II, Open-label, Multi-center Study of Erivedge (Vismodegib) in the Treatment of Pediatric Patients With Refractory Pontine Glioma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2016

At a glance

  • Drugs Vismodegib (Primary)
  • Indications Glioma
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Oct 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
    • 22 May 2013 Planned initiation date changed from 1 Apr 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 25 Mar 2013 Planned initiation date changed from 1 Feb 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top